Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology - ARVN News | RalliesArvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology
A
ARVN• Corporate presentation highlights pipeline and partnership updates
- Arvinas highlighted FDA clearance of VEPPANU (vepdegestrant) on May 1, 2026 for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.
- Global rights to VEPPANU were licensed to Rigel in May 2026, with milestone potential and tiered royalties on net sales.
- Luxdegalutamide was out-licensed to Novartis in 2024, with stated total deal value potential above $1 billion.
- Novartis is running three Phase 2 combination trials for luxdegalutamide across mCRPC and mHSPC settings.
- Arvinas cited more than $800 million in non-dilutive cash from Pfizer and Novartis partnerships, with cash runway into 2H 2028.
